ScientiaLux
Index
QF-Pro Home › QF-Pro Glossary › PD-1/PD-L1
Immune Checkpoints — Step 2 of 5
1Immune Checkpoint
2PD-1/PD-L1
3CTLA-4/CD80
4LAG-3/MHC II
5TIGIT/CD155
Previous
Immune Checkpoint Next
CTLA-4/CD80
Checkpoint Axis

PD-1/PD-L1

The most-targeted checkpoint axis in cancer immunotherapy–where expression fails to predict response but interaction state succeeds.

View
Definition
PD-1 (Programmed Death-1) on T cells binding PD-L1 on tumor or immune cells delivers inhibitory signals that suppress anti-tumor immunity. While PD-L1 expression by IHCLoading... is the current companion diagnosticLoading..., it fails to predict checkpoint inhibitorLoading... response–because expression does not equal engagement. iFRETLoading...-measured PD-1/PD-L1 interaction directly predicts clinical outcome.
Video Segments
Immune Checkpoints Explained
Primary
JCO Clinical Study: 188 NSCLC Patients
Primary
Multi-Checkpoint Immune Signatures
Primary
p=0.05 vs p=0.87
Interaction predicts survival; expression does not
n=176 melanoma
1–10 nm
FRET detection range for true engagement
Validated · Violet 3.0
41%
Response rate even in PD-L1 'high' patients
10 of 11
PD-L1 negative patients with detectable interaction
iFRET validation

The Biology of Checkpoint Suppression

PD-1 is expressed on activated T cells as a natural brake mechanism preventing autoimmunity. Tumor cells exploit this by expressing PD-L1, which binds PD-1 and delivers inhibitory signals that exhaust tumor-infiltrating lymphocytes.

The therapeutic rationale is simple: block this interaction with antibodies (pembrolizumab, nivolumab, atezolizumab) and T cells regain their cytotoxic function. The clinical challenge is identifying which patients will respond–a question that expression-based biomarkers have failed to answer.

Simplified

How It Works: PD-1 on T cells and PD-L1 on tumor cells form a "handshake" that tells the T cell to stop attacking. This is how tumors hide from the immune system.

The Drugs: Anti-PD-1 (pembrolizumab, nivolumab) and anti-PD-L1 (atezolizumab) drugs block this handshake, releasing T cells to attack cancer.

Why Expression Fails as a Biomarker

PD-L1 IHCLoading... measures whether the ligand is present–not whether it is functioning. A tumor may express abundant PD-L1, but if T cells are absent or spatial barriers prevent contact, the checkpoint is not actively suppressing immunity.

In NSCLCLoading..., only 41% of PD-L1-high patients respond to pembrolizumab–meaning 59% receive ineffective therapy despite meeting the biomarker threshold. Conversely, patients classified as PD-L1-negative may have active checkpoint engagement at localized tumor-immune interfaces that IHC cannot detect.

Simplified

The Problem: PD-L1 expression (measured by IHC) is used to select patients, but it's imperfect. Many "negative" patients respond; many "positive" patients don't.

The Reason: Expression tells you if PD-L1 is present—not if it's actually engaging PD-1 to suppress immunity. Presence ≠ function.

iFRET Measures What Matters

iFRET directly quantifies PD-1/PD-L1 engagement by measuring energy transfer between chromophoresLoading... attached to both proteins. Signal occurs only when receptor and ligand are within 1–10 nm–the distance of molecular interaction.

This transforms the biomarker question from 'Is PD-L1 expressed?' to 'Is the checkpoint actively engaged?' The resulting measurement correlates with clinical outcomes where expression fails.

Simplified

The Solution: iFRET directly measures whether PD-1 and PD-L1 are bound together at the 1-10nm scale of genuine molecular interaction.

The Evidence: In 176 melanoma patients, engagement predicted survival (P=0.05); expression didn't (P=0.87). In kidney cancer, 10/11 "PD-L1 negative" patients had FRET-detectable engagement.

QF-Pro Application

Clinically Validated

Clinical Validation: The PD-1/PD-L1 interaction represents the most extensively validated application of QF-Pro technology. In a landmark study of 176 melanoma patients[3], iFRET-measured PD-1/PD-L1 interaction state correlated significantly with overall survival (P=0.05[3]), while PD-L1 expression by IHC showed no prognostic value (P=0.87[3]).

Critically, in clear cell RCC, iFRET detected PD-1/PD-L1 engagement in 10 of 11 patients classified as "PD-L1 negative" by standard IHC–demonstrating functional checkpoint engagement invisible to expression-based assayLoading...s.

Click citation numbers to view full references in QF-Pro Applications & Clinical EvidenceLoading...

Simplified

What this means: QF-Pro can detect when PD-1 and PD-L1 are actually physically interacting, not just present. In 176 melanoma patients, this interaction predicted survival (P=0.05) while traditional expression testing showed nothing (P=0.87). Even patients labeled "PD-L1 negative" often had detectable checkpoint engagement.

Expression-Based Selection
PD-L1 IHC determines therapy eligibility. 'High' expressers receive immunotherapy; 'negative' patients are excluded–yet most high expressers don't respond and some negative patients would benefit.
Interaction-Based Selection
iFRET measures actual PD-1/PD-L1 engagement at the immune synapse. Patients with high interaction state–regardless of expression score–show improved response to checkpoint blockade.

Clinical Validation: Function Predicts Outcome

  • Metastatic melanomaLoading... (n=176): PD-1/PD-L1 interaction state correlated with overall survival (p=0.05); PD-L1 expression showed no correlation (p=0.87)
  • Metastatic NSCLCLoading... (n=40): Anti-PD-1 treated patients with lower interaction state had significantly worsened survival (p=0.05); expression was non-predictive
  • Clear cell RCC: iFRETLoading... detected checkpoint engagement in 10 of 11 patients classified as 'PD-L1 negative' by IHC
  • Neoadjuvant TVEC (2025): Complete responders showed increased iFRETLoading... efficiency post-treatment; non-responders showed unchanged values–not reflected by PD-L1 expression

Connected Terms

Share This Term
Term Connections